正清风痛宁治疗痛风性关节炎有效性及安全性的Meta分析

Meta-Analysis of the Efficacy and Safety of Zhengqingfengtongning in the Treatment of Gouty Arthritis

摘要: 目的：系统评价正清风痛宁治疗痛风性关节炎(GA)的疗效。方法：计算机检索自建库至2024年8月1日相关数据库中有关正清风痛宁治疗痛风性关节炎的随机对照试验(RCT)。提取患者临床有效率、血尿酸水平、红细胞沉降率、C-反应蛋白和不良反应发生率进行统计学分析，系统评价正清风痛宁治疗痛风性关节炎的临床疗效及安全性。结果：本研究共纳入9篇RCT研究，包含582例患者(治疗组292，对照组290)。Meta分析结果显示：正清风痛宁在提高临床有效率(RR = 1.15, 95%CI [1.08, 1.23], Z = 4.23, P < 0.0001)、降低血尿酸(UA)水平(MD = −28.16, 95%CI [−42.03, −14.28], Z = 3.98, P < 0.0001)、降低血沉水平(MD = −2.71, 95%CI [−3.63, −1.80], Z = 5.82, P < 0.00001)等方面优于常规西医治疗，不良反应发生率无统计学差异(RR = 0.28, 95%CI [0.05, 1.59], Z = 1.44, P > 0.05)。结论：正清风痛宁相较于常规西医治疗可以提高对痛风性关节炎的临床疗效且具有良好的安全性。

Abstract: Objective: To systematically evaluate the efficacy of Zhengqingfengtongning in treating gouty arthritis (GA). Methods: Randomized controlled trials (RCTs) on Zhengqingfengtongning for gouty arthritis were retrieved from relevant databases from their inception to August 1, 2024. Data on clinical response rate, serum uric acid (UA) levels, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and adverse event rates were extracted for statistical analysis. A systematic evaluation of the clinical efficacy and safety of Zhengqinfengtongning in treating gouty arthritis was conducted. Results: Nine RCTs involving 582 patients (292 in the treatment group, 290 in the control group) were included. Meta-analysis demonstrated that Zhengqingfengtongning was superior to conventional Western medicine in the following aspects: Clinical response rate RR = 1.15, 95% CI [1.08, 1.23], Z = 4.23, P < 0.0001, reduce blood uric acid (UA) level MD = −28.16, 95%CI [−42.03, −14.28], Z = 3.98, P < 0.0001, reduce blood sedimentation MD = −2.71, 95%CI [−3.63, −1.80], Z = 5.82, P < 0.00001, no statistically significant difference in the incidence of adverse reactions RR = 0.28, 95%CI [0.05, 1.59], Z = 1.44, P > 0.05. Conclusion: Zhengqingfengtongning can improve the clinical efficacy of gouty arthritis compared with conventional Western medical treatment, and it has a good safety profile.